{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T20:08:14Z","timestamp":1775592494780,"version":"3.50.1"},"reference-count":0,"publisher":"Dustri-Verlag Dr. Karl Feistle","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CP"],"published-print":{"date-parts":[[2025,11,1]]},"DOI":"10.5414\/cp204726","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T09:21:26Z","timestamp":1756718486000},"page":"518-529","source":"Crossref","is-referenced-by-count":1,"title":["Phase IV safety evaluation of voclosporin in lupus nephritis patients using the FAERS database for a 42-month period (2021\u00a0\u2013\u00a02024)"],"prefix":"10.5414","volume":"63","author":[{"given":"Bo","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3374","container-title":["Int. Journal of Clinical Pharmacology and Therapeutics"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T07:47:53Z","timestamp":1760946473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dustri.com\/article_response_page.html?artId=192319&doi=10.5414\/CP204726&L=0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":0,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"alternative-id":["204726"],"URL":"https:\/\/doi.org\/10.5414\/cp204726","relation":{},"ISSN":["0946-1965"],"issn-type":[{"value":"0946-1965","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}